These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16361070)

  • 21. Molecular cloning and expression of epsilon toxin from Clostridium perfringens type D and tests of animal immunization.
    Souza AM; Reis JK; Assis RA; Horta CC; Siqueira FF; Facchin S; Alvarenga ER; Castro CS; Salvarani FM; Silva RO; Pires PS; Contigli C; Lobato FC; Kalapothakis E
    Genet Mol Res; 2010 Feb; 9(1):266-76. PubMed ID: 20198582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assembly of Clostridium perfringens epsilon-toxin on MDCK cell membrane.
    Nagahama M; Ochi S; Sakurai J
    J Nat Toxins; 1998 Oct; 7(3):291-302. PubMed ID: 9783265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progress in the replacement of animal experiments in the quality control of clostridial vaccines].
    Cussler K; Borrmann E; Werner E
    Dtsch Tierarztl Wochenschr; 2002 Apr; 109(4):172-7. PubMed ID: 11998369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with recombinant alpha toxin partially protects broiler chicks against experimental challenge with Clostridium perfringens.
    Cooper KK; Trinh HT; Songer JG
    Vet Microbiol; 2009 Jan; 133(1-2):92-7. PubMed ID: 18635321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The protective effect of Clostridium novyi type B alpha-toxoid against challenge with spores in guinea pigs.
    Amimoto K; Sasaki O; Isogai M; Kitajima T; Oishi E; Okada N; Yasuhara H
    J Vet Med Sci; 1998 Jun; 60(6):681-5. PubMed ID: 9673937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of Clostridium perfringens vaccines using an indirect competitive ELISA for the epsilon toxin component - examination of the assay by a collaborative study.
    Rosskopf-Streicher U; Volkers P; Werner E
    Pharmeuropa Bio; 2004 Jan; 2003(2):91-6. PubMed ID: 14960265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potency against enterotoxemia of a recombinant Clostridium perfringens type D epsilon toxoid in ruminants.
    Lobato FC; Lima CG; Assis RA; Pires PS; Silva RO; Salvarani FM; Carmo AO; Contigli C; Kalapothakis E
    Vaccine; 2010 Aug; 28(38):6125-7. PubMed ID: 20670910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a flow cytometric bead immunoassay and its assessment as a possible aid to potency evaluation of enterotoxaemia vaccines.
    Buys A; Macdonald R; Crafford J; Theron J
    J S Afr Vet Assoc; 2014 Mar; 85(1):977. PubMed ID: 24832497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme linked immunosorbent assay for potency testing of vaccines containing Clostridium perfringens type D epsilon-toxoid.
    Pfahler W; Bisesti E; Pereyra JB; Iribarren F
    Zentralbl Veterinarmed B; 1998 Apr; 45(3):133-9. PubMed ID: 9588107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replacement of the in vivo neutralisation test for efficacy demonstration of tetanus vaccines ad us. vet.
    Rosskopf U; Noeske K; Werner E
    ALTEX; 2005; 22(3):169-74. PubMed ID: 16186992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production and evaluation of a monoclonal antibody to Clostridium perfringens type D epsilon toxin.
    El-Enbaawy MI; Abdalla YA; Hussein AZ; Osman RM; Selim SA
    Egypt J Immunol; 2003; 10(1):77-81. PubMed ID: 15719625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
    Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
    J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Purification, characterisation and production of a monoclonal antibody to Cl. novyi type B alpha toxin.
    Whitworth K
    Dev Biol Stand; 1996; 86():347. PubMed ID: 8785987
    [No Abstract]   [Full Text] [Related]  

  • 34. Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C.
    Neeson BN; Clark GC; Atkins HS; Lingard B; Titball RW
    Microb Pathog; 2007 Oct; 43(4):161-5. PubMed ID: 17604945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time multiplex PCR assays for reliable detection of Clostridium perfringens toxin genes in animal isolates.
    Albini S; Brodard I; Jaussi A; Wollschlaeger N; Frey J; Miserez R; Abril C
    Vet Microbiol; 2008 Feb; 127(1-2):179-85. PubMed ID: 17855025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Requirements for valid alternative assays for testing of biological therapeutic agents.
    Sesardic D
    Dev Biol Stand; 1996; 86():311-8. PubMed ID: 8785962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro tests for the measurement of clostridial toxins, toxoids and antisera. II. Titration of Clostridium perfringens toxins and antitoxins in cell culture.
    Knight PA; Queminet J; Blanchard JH; Tilleray JH
    Biologicals; 1990 Oct; 18(4):263-70. PubMed ID: 2285500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of Clostridium novyi type B alpha toxin using cell culture systems.
    Borrmann E; Schulze F
    ALTEX; 1998; 15(5):53-56. PubMed ID: 11178542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standardization and validation of Vero cell assay for potency estimation of diphtheria antitoxin serum.
    Kumar S; Kanwar S; Bansal V; Sehgal R
    Biologicals; 2009 Oct; 37(5):297-305. PubMed ID: 19540135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An international survey of clostridial sera and vaccines.
    Davidson I
    Dev Biol Stand; 1976; 32():3-14. PubMed ID: 187508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.